KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $14.7 million.

  • Recursion Pharmaceuticals' Other Operating Expenses rose 2159.12% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 6413.7%. This contributed to the annual value of $45.2 million for FY2024, which is 622.49% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Other Operating Expenses stood at $14.7 million, which was up 2159.12% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Other Operating Expenses ranged from a high of $21.8 million in Q1 2025 and a low of $7.8 million during Q1 2022
  • Its 4-year average for Other Operating Expenses is $12.9 million, with a median of $12.1 million in 2024.
  • In the last 5 years, Recursion Pharmaceuticals' Other Operating Expenses crashed by 3405.5% in 2023 and then skyrocketed by 11916.51% in 2025.
  • Recursion Pharmaceuticals' Other Operating Expenses (Quarter) stood at $10.8 million in 2022, then dropped by 8.85% to $9.9 million in 2023, then increased by 29.48% to $12.8 million in 2024, then grew by 14.8% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $20.2 million for Q2 2025, and $21.8 million during Q1 2025.